US FDA clears Everest Medicines’ IND application for tumour-associated antigen vaccine, EVM14: Shanghai, China Tuesday, March 25, 2025, 15:00 Hrs [IST] Everest Medicines, a biop ...

The method triggers immune responses that inhibit melanoma, triple-negative breast cancer, lung carcinoma, and ovarian cancer ...

Since the first such tumour antigens were identified in the early 1990s by Thierry Boon, a biologist at the Ludwig Institute for Cancer Research, Brussels, Belgium, enthusiasm for cancer vaccines ...

EVM14 received FDA clearance for clinical trials, marking Everest Medicines’ first in-house developed therapeutic to reach ...

RNA cancer vaccines are at the forefront of next-generation cancer immunotherapy, showcasing significant potential.

Black and American Indian patients are less likely to have elevated cancer antigen-125 levels at ovarian cancer diagnosis.

In this cohort study of patients with ovarian cancer, American Indian and Black patients were 23% less likely to have an elevated cancer antigen (CA)-125 level at diagnosis. Current CA-125 thresholds ...

EVM14 received U.S. FDA clearance for its IND application, becoming Everest's first internally discovered program, and the first mRNA therapeutic cancer vaccine to be cleared for global clinical ...